Status:
COMPLETED
A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect information about the participant's ability and willingness to pay for NovoMix 30 using a modern device, which is prescribed to the participant by the study doc...
Eligibility Criteria
Inclusion
- The decision to initiate treatment with commercially available BIAsp 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study - Patients selected by their physician for participation in the study, who are likely to be able and willing to pay for the BIAsp 30 treatment for at least 12 weeks from baseline visit as assessed by the treating physician - Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) - Male or female greater than or equal to 18 years at time of informed consent - Diagnosed with T2DM and treated with BHI in vials for at least three consecutive months at time of informed consent
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study - Concurrent participation in any other clinical trial or study - Patients previously treated with insulin analogues - Known or suspected hypersensitivity to study product (or any of the excipients of the study product; a full list of excipients is provided in Summary of product characteristics (SmPC) of NovoMix® 30) or related products - Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation - Patients who are unable to read or write (illiterate)
Key Trial Info
Start Date :
November 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 4 2018
Estimated Enrollment :
516 Patients enrolled
Trial Details
Trial ID
NCT03374774
Start Date
November 13 2017
End Date
July 4 2018
Last Update
August 31 2018
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Guwahati, Assam, India, 781006
2
Novo Nordisk Investigational Site
Ahmedabad, Gujarat, India, 380054
3
Novo Nordisk Investigational Site
Bangalore, Karnataka, India, 560092
4
Novo Nordisk Investigational Site
Bangalore, Karnataka, India